|
參考文獻： [1]?Ramalingam, et al. Overall Survival with Osimertinib in Untreated,?EGFR-Mutated Advanced NSCLC.?The New England journal of medicine?vol. 382,1 (2020): 41-50. doi:10.1056/NEJMoa1913662[2]?Lu, S., et al.（2022）. Efficacy of Aumolertinib（HS-10296）in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational?Trial. J Thorac Oncol 17, 411-422.[3] Lu S, et al. Randomized phase Ⅲ?trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm). ASCO 2021. Abstr 9013.[4] H.l.Chen, et al. Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial (ALWAYS).[5]?Sanjay Popat,?et al. Indirect treatment comparisons of relative efficacy for aumolertinib VS?osimertinib in EGFR-positive non-small cell lung cancer (NSCLC).?ESMO 2022.?1005P.
|